Special Notice
1. This article is intended strictly for internal industry exchanges and information sharing within the vaping/tobacco trade, and does not constitute an endorsement or recommendation of any brand or product.
2. All images and visuals presented herein are solely used for objective factual description and news reporting, and do not serve as commercial advertising or marketing for any product.
3. Access to this content by minors is strictly prohibited.
Key Points
- FOGER applies a 6-MN-related formulation to the existing Switch Pro 30K pod platform.
- The product retains the reusable dock and magnetic replacement pod architecture.
- The Nixodine version is labeled nicotine-free for conventional nicotine while using a 5% Nixodine formulation.
- The pod keeps Normal/Boost modes, dual-mesh heating and adjustable airflow.
- U.S. retail and wholesale listings appeared in August 2026.
- The product involves an emerging nicotine-analogue formulation with evolving regulatory considerations.
2Firsts
August 27, 2026
According to U.S. retail and wholesale listings, FOGER introduced the Switch Pro 30K Nixodine Pod in August 2026, bringing a 6-methylnicotine (6-MN)-related formulation into the existing Switch Pro 30K ecosystem.
The product is not a new hardware platform. Instead, it is a formulation variant built on the existing Switch Pro 30K system, maintaining the reusable dock and magnetic replacement pod architecture while introducing a different active-ingredient approach.
Nixodine Version Introduces 6-MN Related Formulation
The FOGER Switch Pro 30K Nixodine Pod retains the existing architecture consisting of:
● Reusable battery dock;
● Magnetic prefilled replacement pod.
Unlike the standard Switch Pro 30K pod, which uses 5% nicotine salt, the Nixodine version is labeled as containing no conventional nicotine and uses a 5% Nixodine-related formulation.
The primary difference is the formulation rather than the hardware platform.
Product specifications:
Parameter | Information |
Brand | FOGER |
Product Name | Switch Pro 30K Nixodine Pod |
Product Category | Prefilled replacement pod |
System Architecture | Reusable dock + magnetic pod |
E-Liquid Capacity | 19ml |
Claimed Puff Count | Up to 30,000 Normal; up to 18,000 Boost* |
Active Ingredient | Nixodine; 6-methylnicotine-related formulation |
Conventional Nicotine | Labeled nicotine-free |
Formula Strength | 5% Nixodine |
Coil | 1.0Ω dual mesh |
Modes | Normal; Boost |
Airflow | Adjustable |
Activation | Draw-activated |
Display & Interaction | Dock OLED; magnetic connection |
Battery & Charging | Pod 200mAh; dock 850mAh; USB-C |
Compatible Hardware | FOGER Switch Pro 30K dock |
Price | US$24.99 retail listing |
Launch Timing | U.S. retail listings: August 2026 |
Launch Type | 6-MN formulation pod variant |
Key Market | United States |
*Puff counts are manufacturer/retailer-rated maximums; actual use may vary depending on mode and usage conditions.
Existing Switch Pro 30K Platform Retained
The Switch Pro 30K Nixodine Pod maintains the same hardware approach as the existing Switch Pro 30K platform.
The system continues to use:
● Reusable battery dock;
● Magnetic pod connection;
● OLED display;
● Normal and Boost modes.
The hardware retains dual-mesh heating and adjustable airflow, while the main change is the formulation inside the pod.
U.S. Retail Appearance With Limited Availability Information
Public information shows the Switch Pro 30K Nixodine Pod appearing across U.S. retail and wholesale channels in August 2026.
Some retail listings indicate Kentucky-only availability, while public information does not confirm a nationwide rollout schedule.
Retail listings show a price of approximately: US$24.99
Availability, pricing and distribution may vary by retailer and market.
Emerging Nicotine-Analogue Formulations Enter High-Capacity Pod Systems
The primary significance of the Switch Pro 30K Nixodine Pod is not a hardware upgrade, but the introduction of a 6-MN-related formulation into an established high-capacity pod ecosystem.
Products using 6-MN and related nicotine-analogue formulations have emerged in markets seeking alternatives to conventional nicotine products. However, their regulatory status, long-term evidence base and market positioning remain under development.
The use of “Nixodine” or “nicotine-free” labeling does not indicate regulatory approval or a settled regulatory classification.
As of publication, no public information indicates that the Switch Pro 30K Nixodine Pod has received FDA marketing authorization.
Industry Perspective
FOGER’s Nixodine launch highlights how some vape companies are exploring active-ingredient alternatives beyond conventional nicotine while leveraging existing high-capacity hardware ecosystems.
Unlike traditional flavor or design updates, the Nixodine Pod represents a formulation-based expansion within an existing device platform.
The development suggests that competition in high-capacity pod systems is expanding beyond:
● Battery capacity;
● E-liquid volume;
● Puff-count claims;
toward:
● Active-ingredient innovation;
● Product positioning;
● Regulatory-boundary exploration.
The long-term research base, regulatory pathway and consumer acceptance of these emerging formulations remain areas to watch.
Follow 2Firsts for the latest developments in global vaping and next-generation nicotine products, product launches, innovation, technology and market trends.
Cover image source: vapesourcing
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
